These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11041257)

  • 21. Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle.
    Karim A; Burns T; Wearley L; Streicher J; Palmer M
    Clin Pharmacol Ther; 1985 Jul; 38(1):77-83. PubMed ID: 4006379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silk fibroin as a novel coating material for controlled release of theophylline.
    Bayraktar O; Malay O; Ozgarip Y; Batigün A
    Eur J Pharm Biopharm; 2005 Aug; 60(3):373-81. PubMed ID: 15996578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theophylline controlled-release formulations: in vivo-in vitro correlations.
    Yu Z; Schwartz JB; Sugita ET
    Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Contin delivery system: dosing considerations.
    Leslie S
    J Allergy Clin Immunol; 1986 Oct; 78(4 Pt 2):768-73. PubMed ID: 3771963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of curdlan to controlled drug delivery. I. The preparation and evaluation of theophylline-containing curdlan tablets.
    Kanke M; Koda K; Koda Y; Katayama H
    Pharm Res; 1992 Mar; 9(3):414-8. PubMed ID: 1614977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissolution of theophylline from film-coated slow release mini-tablets in various dissolution media.
    Fassihi AR; Munday DL
    J Pharm Pharmacol; 1989 Jun; 41(6):369-72. PubMed ID: 2570830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-unit dosage formulations of theophylline for controlled release applications.
    Uhumwangho MU; Okor RS
    Acta Pol Pharm; 2007; 64(6):553-9. PubMed ID: 18323251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of pH on the in vitro dissolution and in vivo absorption of controlled-release theophylline in dogs.
    Vashi VI; Meyer MC
    J Pharm Sci; 1988 Sep; 77(9):760-4. PubMed ID: 3225770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter comparison of once-daily Uniphyl tablets administered in the morning or evening with baseline twice-daily theophylline therapy in patients with nocturnal asthma.
    Grossman J
    Am J Med; 1988 Jul; 85(1B):11-3. PubMed ID: 3041821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of an extended-release theophylline product in cats.
    Guenther-Yenke CL; McKiernan BC; Papich MG; Powell E
    J Am Vet Med Assoc; 2007 Sep; 231(6):900-6. PubMed ID: 17867974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of once-daily Uniphyl tablets compared with twice-daily Theo-Dur tablets in elderly patients with chronic airflow obstruction.
    Rivington RN; Calcutt L; Hodder RV; Stewart JH; Aitken TL
    Am J Med; 1988 Jul; 85(1B):48-53. PubMed ID: 3041826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving of the accuracy of in vitro-in vivo linear correlation using kinetic models for ultra sustained release theophylline tablets.
    Karasulu E; Aktogu S; Karasulu HY; Aydogdu A; Tuglular I; Ertan G
    Eur J Drug Metab Pharmacokinet; 2003; 28(4):301-7. PubMed ID: 14743972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and evaluation of a controlled-release theophylline tablet. Preliminary communication.
    Gai MN; Pezoa R; Corbeaux J; Arancibia A
    Farmaco; 1989 Nov; 44(11):1119-26. PubMed ID: 2701966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of in vitro dissolution of whole vs. half controlled-release theophylline tablets.
    Shah VP; Yamamoto LA; Schuirman D; Elkins J; Skelly JP
    Pharm Res; 1987 Oct; 4(5):416-9. PubMed ID: 3508552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Theophylline release and diffusion from a compressed ethylcellulose matrix through an artificial membrane].
    Noureddine N; Douki W; Chaumeil JC; Sfar S
    Ann Pharm Fr; 2004 Sep; 62(5):343-7. PubMed ID: 15314582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of acryclic and metacrylic acid derivatives as sustained release matrices for theophylline hydrate tablets.
    Ofoefule SI; Chukwu A
    Boll Chim Farm; 1999 Nov; 138(10):526-30. PubMed ID: 10765469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formation of water-insoluble gel in dry-coated tablets for the controlled release of theophylline.
    Kaneko K; Kanada K; Miyagi M; Saito N; Ozeki T; Yuasa H; Kanaya Y
    Chem Pharm Bull (Tokyo); 1998 Apr; 46(4):728-9. PubMed ID: 9579051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A floating controlled-release drug delivery system: in vitro-in vivo evaluation.
    Desai S; Bolton S
    Pharm Res; 1993 Sep; 10(9):1321-5. PubMed ID: 8234170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Per-oral controlled release dosage form of theophylline using soybean protein.
    Machida Y; Tokumura T; Nagai T
    Drug Des Deliv; 1987 Feb; 1(3):187-92. PubMed ID: 3509332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative bioavailability and bioequivalence study of theophylline sustained release formulations.
    Vergin H; Mahr G; Winterhalter B; Wigand R
    Arzneimittelforschung; 2003; 53(9):635-9. PubMed ID: 14558437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.